SCHEMBL400298

SCHEMBL400298

COC(=O)c1cc(OC)c(OC(=O)CCCc2ccc(NC(=O)c3ccc(C)nc3-c3ccc(C(F)(F)F)cc3)c(C(=O)N(C)C)c2)c(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 1/20 0.41
NTRK2 Q16620 1/20 0.41
PPARA Q07869 4/20 0.39
PPARG P37231 1/20 0.39
MTTP P55157 5/20 0.36
CYP3A4 P08684 2/20 0.33
CYP2C19 P33261 2/20 0.33
PLK1 P53350 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
PPARD Q03181 1/20 0.33
KCNH2 Q12809 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
RXFP1 Q9HBX9 1/20 0.32
ROCK2 O75116 1/20 0.32
ROCK1 Q13464 1/20 0.32
MAPT P10636 1/20 0.32
DRD2 P14416 1/20 0.32
DRD3 P35462 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL401876 0.97 NTRK1 (0.39) NTRK1NTRK2PPARAPPARGMTTP
SCHEMBL403369 0.97 NTRK1 (0.39) NTRK1NTRK2PPARAPPARGMTTP
SCHEMBL400194 0.97 NTRK1 (0.39) NTRK1NTRK2PPARAPPARGMTTP
SCHEMBL401638 0.96 NTRK1 (0.38) NTRK1NTRK2PPARAPPARGMTTP
SCHEMBL399641 0.95 NTRK1 (0.39) NTRK1NTRK2PPARAPPARGMTTP
SCHEMBL397835 0.95 NTRK1 (0.39) NTRK1NTRK2PPARAPPARGMTTP
SCHEMBL400572 0.95 NTRK1 (0.39) NTRK1NTRK2PPARAPPARGMTTP
SCHEMBL402008 0.95 NTRK1 (0.41) NTRK1NTRK2PPARAPPARGMTTP
SCHEMBL5316647 0.95 NTRK1 (0.41) NTRK1NTRK2PPARAPPARGMTTP
SCHEMBL403475 0.94 NTRK1 (0.39) NTRK1NTRK2PPARAPPARGMTTP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060089392-A1 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-04-27 US claimed
US-8101774-B2 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2012-01-24 US disclosed
US-8101774-B2 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2012-01-24 US disclosed
US-8101774-B2 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2012-01-24 US disclosed
EP-1803452-A1 ESTER DERIVATIVE AND PHARMACEUTICAL USE THEREOF Japan Tobacco, Inc. (JP) 2007-07-04 EP disclosed
US-20060089392-A1 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089392-A1 Ester derivatives and medicinal use thereof MTTP, CETP, LIPA NTRK1 3420/4885NTRK2 2775/4885PPARA 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.